Home › Therapeutic areas › Oncology › Lymphoma
Lymphoma (16 companies)
Companies with an active program in Lymphoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ADCT | ADC Therapeutics | Oncology | 3 | Approved | $202M | 5 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 | 1 | NDA Submitted | $38.3M | 5 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $360M | 10 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | $420M | 10 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 2 | Approved | $341M | 12 |
| CLRB | Cellectar Biosciences | Oncology | 1 | Phase 2 | $11.8M | 6 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 1 | Phase 3 | $889M | 7 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $9.15B | 16 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | $2.13B | 9 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 1 | Phase 2 | $82.0M | 13 |
| LEGN | Legend Biotech | Oncology Rare | 4 | Approved | $4.55B | 17 |
| MRKR | Marker Therapeutics | Oncology | 1 | Phase 1 | $14.8M | 4 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | $1.27B | 11 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 3 | Phase 3 | $1.67B | 13 |
| SANA | Sana Biotechnology | MetabolicOncology | 1 | Phase 1 | $710M | 4 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 2 | Approved | $2.68B | 28 |
No companies match.